Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives

Major depressive disorder (MDD) remains a leading global cause of disability, with substantial clinical and societal burden. Despite the wide availability of antidepressants, many patients experience inadequate response, partial remission, or treatment-resistant depression. Emerging pharmacological options beyond traditional monoaminergic agents have shown promise in phase 3 clinical trials, yet their integration into treatment algorithms remains limited.

This review summarizes current challenges in antidepressant therapy and examines phase 3 clinical evidence for newer agents across diverse depressive conditions, including postpartum depression, acute suicidal ideation, and treatment-resistant MDD. Data on efficacy, safety, and relapse prevention from pivotal trials of brexanolone, intranasal esketamine, dextromethorphan - bupropion, vortioxetine, and metabolism-based interventions such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are discussed. The positioning of these treatments within international clinical guidelines is also examined, highlighting inconsistencies and the lack of formal recommendations. A literature search was conducted in PubMed, Embase, Scopus, and ClinicalTrials.gov from January 2000 to June 2025.

Newer antidepressants represent a shift beyond conventional approaches, offering rapid symptom relief and potential cognitive or metabolic benefits. However, limited guideline integration, insufficient long-term data, and implementation barriers restrict their clinical uptake. Clearer sequencing strategies and harmonized recommendations are needed to support more individualized depression management.